NEK11 Inhibitors
1 drugsAbout NEK11
NEK11, or NIMA-related kinase 11, is a protein kinase involved in regulating cellular processes through phosphorylation. Its dysregulation is often implicated in disease, making it a target of interest, particularly in oncology.
NEK11 is a therapeutic target in oncology, though there is currently no genetic evidence data available linking it to specific diseases. Targeting NEK11 has the potential to disrupt cancer cell growth and survival.
NEK11 is targeted by one FDA-approved drug, TAFINLAR (Novartis), a small molecule with 4 indications in oncology. TAFINLAR was first approved in 2013, and no other drugs have been approved since.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Advanced Lymphoma with only 2 trials.
- phase1 represents biological uncertainty with 55% completion.
Top Drugs
Novartis is the only company with an approved drug targeting NEK11.
Low competition suggests a potential first-mover advantage, but also indicates higher risk due to lack of validation by others.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets NEK11, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches like antibodies or PROTACs.
Clinical Trials 131 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 47 | 25 | 13 | 8 | 66% |
| Phase 2 | 60 | 21 | 16 | 23 | 57% |
| Phase 3 | 18 | 12 | 1 | 5 | 92% |
| Phase 4 | 6 | 1 | 1 | 3 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2013 - 2013)
The first and only drug targeting NEK11, TAFINLAR, was approved in 2013.
The lack of recent approvals suggests saturation or challenges in developing further NEK11-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 84 clinical trials targeting NEK11.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities